- Home
- GNPX vs TRNR Comparison
GNPX vs TRNR Comparison
Compare GNPX & TRNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- TRNR
- Stock Information
- Founded
- GNPX 2009
- TRNR 2017
- Country
- GNPX United States
- TRNR United States
- Employees
- GNPX N/A
- TRNR N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- TRNR Consumer Electronics/Appliances
- Sector
- GNPX Health Care
- TRNR Technology
- Exchange
- GNPX Nasdaq
- TRNR Nasdaq
- Market Cap
- GNPX 854.2K
- TRNR 836.6K
- IPO Year
- GNPX 2018
- TRNR 2023
- Fundamental
- Price
- GNPX $0.93
- TRNR $2.96
- Analyst Decision
- GNPX Strong Buy
- TRNR
- Analyst Count
- GNPX 1
- TRNR 0
- Target Price
- GNPX $10.00
- TRNR N/A
- AVG Volume (30 Days)
- GNPX 877.2K
- TRNR 1.9M
- Earning Date
- GNPX 11-13-2024
- TRNR 11-14-2024
- Dividend Yield
- GNPX N/A
- TRNR N/A
- EPS Growth
- GNPX N/A
- TRNR N/A
- EPS
- GNPX N/A
- TRNR N/A
- Revenue
- GNPX N/A
- TRNR $3,180,000.00
- Revenue This Year
- GNPX N/A
- TRNR $1,543.45
- Revenue Next Year
- GNPX N/A
- TRNR $54.84
- P/E Ratio
- GNPX N/A
- TRNR N/A
- Revenue Growth
- GNPX N/A
- TRNR 226.82
- 52 Week Low
- GNPX $0.28
- TRNR $2.50
- 52 Week High
- GNPX $14.40
- TRNR $4,760.00
- Technical
- Relative Strength Index (RSI)
- GNPX 42.91
- TRNR 34.95
- Support Level
- GNPX $0.82
- TRNR $2.85
- Resistance Level
- GNPX $0.96
- TRNR $3.40
- Average True Range (ATR)
- GNPX 0.09
- TRNR 0.31
- MACD
- GNPX -0.00
- TRNR 0.38
- Stochastic Oscillator
- GNPX 27.36
- TRNR 27.73
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.